Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C.
Phase of Trial: Phase IV
Latest Information Update: 23 May 2013
At a glance
- Drugs Peginterferon alfa (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 18 Oct 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2010 Planned number of patients changed from 1803 to 2500 as reported by ClinicalTrials.gov.